<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00103220</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01462</org_study_id>
    <secondary_id>NCI-2012-01462</secondary_id>
    <secondary_id>MSKCC-04076</secondary_id>
    <secondary_id>CDR0000409581</secondary_id>
    <secondary_id>NCI-6818</secondary_id>
    <secondary_id>04-076</secondary_id>
    <secondary_id>6818</secondary_id>
    <secondary_id>U01CA069856</secondary_id>
    <nct_id>NCT00103220</nct_id>
  </id_info>
  <brief_title>SJG-136 in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Study With SJG-136 (NSC #694501) in Patients With an Advanced Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of SJG-136 in treating patients&#xD;
      with advanced solid tumors. Drugs used in chemotherapy, such as SJG-136, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the toxicities, pharmacokinetic profile and the recommended phase 2 dose of&#xD;
      SJG-136 in patients with an advanced solid tumor.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine preliminary efficacy data and evaluation of correlative markers of DNA damage&#xD;
      and apoptosis in peripheral blood lymphocytes.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study.&#xD;
&#xD;
      Patients receive SJG-136 intravenously (IV) over 20 minutes on days 1, 8, and 15. Courses&#xD;
      repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts&#xD;
      of 3-6 patients receive escalating doses of SJG-136 until the maximum tolerated dose (MTD) is&#xD;
      determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients&#xD;
      experience dose-limiting toxicity. At least 6 patients are treated at the MTD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended phase 2 dose of SJG-136</measure>
    <time_frame>Day 28</time_frame>
    <description>Defined as when ≤1 out of 6 patients achieve dose-limiting toxicity (DLT) at highest dose level below the maximally administered dose.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment (SJG-136)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive SJG-136 IV over 20 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SJG-136</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (SJG-136)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed solid tumor&#xD;
&#xD;
               -  Advanced disease, defined as metastatic or unresectable disease&#xD;
&#xD;
          -  Measurable indicator lesions&#xD;
&#xD;
          -  Standard curative or palliative measures do not exist or are no longer effective&#xD;
&#xD;
          -  Previously treated CNS metastases allowed provided patient has completed local therapy&#xD;
             AND corticosteroids have been discontinued for at least 4 weeks&#xD;
&#xD;
          -  No known leptomeningeal metastases&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Performance status - Karnofsky 60-100%&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin ≤ 1.0 mg/dL&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine &lt; 1.4 mg/dL&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No recent myocardial infarction&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No history of allergic reaction attributed to compounds of similar chemical or&#xD;
             biological composition to study drug&#xD;
&#xD;
          -  No other significant medical history, unstable medical condition, or unstable systemic&#xD;
             disease that would preclude study participation&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas and 8&#xD;
             weeks for UCN-01)&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to ≥ 25% of hematopoietic bone marrow&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  At least 4 weeks since prior investigational anticancer drugs&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naiyer Rizvi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>February 7, 2005</study_first_submitted>
  <study_first_submitted_qc>February 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2005</study_first_posted>
  <last_update_submitted>December 10, 2013</last_update_submitted>
  <last_update_submitted_qc>December 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

